ATE262586T1 - Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin - Google Patents
Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzinInfo
- Publication number
- ATE262586T1 ATE262586T1 AT95943342T AT95943342T ATE262586T1 AT E262586 T1 ATE262586 T1 AT E262586T1 AT 95943342 T AT95943342 T AT 95943342T AT 95943342 T AT95943342 T AT 95943342T AT E262586 T1 ATE262586 T1 AT E262586T1
- Authority
- AT
- Austria
- Prior art keywords
- egf receptor
- type iii
- mutant egf
- fusion junction
- junction type
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000004927 fusion Effects 0.000 title abstract 2
- 102000001301 EGF receptor Human genes 0.000 abstract 4
- 108060006698 EGF receptor Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 abstract 1
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 1
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 abstract 1
- 230000005740 tumor formation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34752094A | 1994-11-28 | 1994-11-28 | |
| PCT/US1995/015401 WO1996016988A1 (en) | 1994-11-28 | 1995-11-28 | Reagents and processes for targeting mutant epidermal growth factor receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE262586T1 true ATE262586T1 (de) | 2004-04-15 |
Family
ID=23364052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95943342T ATE262586T1 (de) | 1994-11-28 | 1995-11-28 | Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6224868B1 (de) |
| EP (1) | EP0796277B1 (de) |
| JP (2) | JP4620808B2 (de) |
| AT (1) | ATE262586T1 (de) |
| CA (1) | CA2206343C (de) |
| DE (1) | DE69532767T2 (de) |
| WO (1) | WO1996016988A1 (de) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996016988A1 (en) * | 1994-11-28 | 1996-06-06 | Thomas Jefferson University | Reagents and processes for targeting mutant epidermal growth factor receptors |
| US5914269A (en) | 1997-04-04 | 1999-06-22 | Isis Pharmaceuticals, Inc. | Oligonucleotide inhibition of epidermal growth factor receptor expression |
| AU784293B2 (en) * | 1999-07-30 | 2006-03-02 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Human P53 mutations and a genetic system in yeast for functional indentification of human P53 mutations |
| US7829693B2 (en) * | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| CA2408175A1 (en) * | 2000-03-10 | 2001-09-20 | Thomas Jefferson University | Sensitive detection of wild-type and mutant egfr by specific elisa assays in any biological sample |
| US6444465B1 (en) | 2000-09-29 | 2002-09-03 | Isis Pharmaceuticals, Inc. | Antinsense modulation of Her-1 expression |
| US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| EP1392359B2 (de) | 2001-05-11 | 2013-03-13 | Ludwig Institute for Cancer Research Ltd. | Spezifische bindungsproteine und ihre verwendung |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| CA2448109A1 (en) | 2001-05-25 | 2002-12-05 | Thomas Jefferson University | Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| US20050175625A1 (en) * | 2002-07-12 | 2005-08-11 | The Johns Hopkins University | Mesothelin vaccines and model systems |
| US20090110702A1 (en) | 2002-07-12 | 2009-04-30 | The Johns Hopkins University | Mesothelin Vaccines and Model Systems and Control of Tumors |
| US9200036B2 (en) | 2002-07-12 | 2015-12-01 | The Johns Hopkins University | Mesothelin vaccines and model systems |
| US20040147428A1 (en) * | 2002-11-15 | 2004-07-29 | Pluenneke John D. | Methods of treatment using an inhibitor of epidermal growth factor receptor |
| US7084246B2 (en) * | 2003-04-17 | 2006-08-01 | Molecular Logix, Inc. | Epidermal growth factor agonists |
| AU2011265359B9 (en) * | 2003-06-27 | 2014-04-10 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| AU2004259398A1 (en) | 2003-06-27 | 2005-02-03 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| CN1930187B (zh) * | 2003-06-27 | 2015-08-19 | 艾默根佛蒙特有限公司 | 针对表皮生长因子受体的缺失突变体的抗体及其使用 |
| AU2012268864B2 (en) * | 2003-06-27 | 2016-01-21 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| AU2015242981B2 (en) * | 2003-06-27 | 2017-10-19 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| US9399662B2 (en) * | 2005-11-02 | 2016-07-26 | Duke University | Concurrent chemotherapy and immunotherapy |
| US9090693B2 (en) | 2007-01-25 | 2015-07-28 | Dana-Farber Cancer Institute | Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease |
| US9340601B2 (en) * | 2007-03-01 | 2016-05-17 | The Board Of Trustees Of The Leland Stanford Junior University | Splice variants of the EGF receptor |
| US9023356B2 (en) | 2007-03-15 | 2015-05-05 | Ludwig Institute For Cancer Research Ltd | Treatment method using EGFR antibodies and SRC inhibitors and related formulations |
| ES2609915T3 (es) | 2007-08-14 | 2017-04-25 | Ludwig Institute For Cancer Research Ltd. | Anticuerpo monoclonal 175 direccionado al receptor de EGF y derivados y usos del mismo |
| WO2009102493A2 (en) * | 2008-02-12 | 2009-08-20 | The Board Of Trustees Of The Leland Stanford Junior University | Use of egfrviii to identify and target cancer stem cells |
| EP2690175B1 (de) | 2008-09-02 | 2016-12-28 | Alnylam Pharmaceuticals, Inc. | Zusammensetzungen und Verfahren zur kombinierten Hemmung der Expression eines mutierenden EGFR-Gens und IL-6 |
| SG10201408505SA (en) | 2009-12-22 | 2015-02-27 | Celldex Therapeutics Inc | Vaccine compositions |
| CN103415620B (zh) * | 2010-11-17 | 2016-10-12 | 艾杜罗生物科技公司 | 诱导针对EGFRvIII的免疫应答的方法和组合物 |
| CA2919907A1 (en) | 2012-08-02 | 2014-02-06 | The Board Of Trustees Of The Leland Stanford Junior University | Peptide vaccines based on the egfrviii sequence for the treatment of tumors |
| US9752145B2 (en) | 2014-03-17 | 2017-09-05 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods for reducing C/EBP homologous protein activity in myeloid-derived suppressor cells |
| BR112016021717A2 (pt) | 2014-03-21 | 2018-07-10 | Abbvie Inc | anticorpos anti-egfr e conjugados anticorpo-fármaco |
| WO2016084993A1 (ko) * | 2014-11-25 | 2016-06-02 | 주식회사 파멥신 | 신규 EGFRvIII 항체 및 이를 포함하는 조성물 |
| WO2016168214A2 (en) | 2015-04-13 | 2016-10-20 | Aduro Biotech, Inc. | Immunogenic fusion proteins for the treatment of cancer |
| KR20180002640A (ko) | 2015-04-13 | 2018-01-08 | 아두로 바이오테크, 인코포레이티드 | 표피 성장 인자 수용체 변형 iii-메소텔린 융합체 및 이를 이용하는 방법 |
| WO2017142294A1 (ko) * | 2016-02-15 | 2017-08-24 | 사회복지법인 삼성생명공익재단 | EGFRvIII에 대한 항체 및 이의 용도 |
| KR101887977B1 (ko) | 2016-02-15 | 2018-08-14 | 사회복지법인 삼성생명공익재단 | EGFRvIII (Epidermal Growth Factor Receptor Variant III)에 대한 항체 및 이의 용도 |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69025946T2 (de) * | 1989-09-08 | 1996-10-17 | Univ Duke | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
| JP2690814B2 (ja) * | 1991-09-03 | 1997-12-17 | 山之内製薬株式会社 | ピラゾロトリアゾール誘導体 |
| CA2261433A1 (en) | 1993-12-09 | 1995-06-10 | Belinda Sanchez Ramirez | Composition comprising autologous epidermal growth factor |
| WO1996016988A1 (en) * | 1994-11-28 | 1996-06-06 | Thomas Jefferson University | Reagents and processes for targeting mutant epidermal growth factor receptors |
-
1995
- 1995-11-28 WO PCT/US1995/015401 patent/WO1996016988A1/en active IP Right Grant
- 1995-11-28 EP EP95943342A patent/EP0796277B1/de not_active Expired - Lifetime
- 1995-11-28 JP JP51898296A patent/JP4620808B2/ja not_active Expired - Lifetime
- 1995-11-28 DE DE69532767T patent/DE69532767T2/de not_active Expired - Lifetime
- 1995-11-28 AT AT95943342T patent/ATE262586T1/de not_active IP Right Cessation
- 1995-11-28 CA CA002206343A patent/CA2206343C/en not_active Expired - Lifetime
-
1997
- 1997-05-21 US US08/861,423 patent/US6224868B1/en not_active Expired - Lifetime
-
2007
- 2007-06-26 JP JP2007167580A patent/JP2007297398A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2206343C (en) | 2009-04-07 |
| JP4620808B2 (ja) | 2011-01-26 |
| CA2206343A1 (en) | 1996-06-06 |
| JPH10509878A (ja) | 1998-09-29 |
| EP0796277B1 (de) | 2004-03-24 |
| DE69532767D1 (en) | 2004-04-29 |
| EP0796277A4 (de) | 2001-01-24 |
| DE69532767T2 (de) | 2004-08-12 |
| JP2007297398A (ja) | 2007-11-15 |
| EP0796277A1 (de) | 1997-09-24 |
| US6224868B1 (en) | 2001-05-01 |
| WO1996016988A1 (en) | 1996-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE262586T1 (de) | Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin | |
| NO20001768D0 (no) | Viruskapsomervaksine, fremgangsmåte til fremstilling samt anvendelse derav | |
| NZ514228A (en) | Method of Expressing Antigens on the Surface of Antigen Presenting Cells by Photochemical Internalisation | |
| WO2001098335A3 (en) | Transgenic algae for delivering antigens to an animal | |
| MA24638A1 (fr) | Vaccin | |
| WO2005066204A3 (en) | Neutralizing epitope-based growth enhancing vaccine | |
| NZ331176A (en) | Receptor protein designated 2F1, DNA encoding 2F1, preparation and use thereof | |
| IL138075A0 (en) | Vaccines, immunotherapeutics and methods for using the same | |
| ES2113088T3 (es) | Metodo de entrega de agentes a celulas diana. | |
| EP1245676A4 (de) | Humane monoklonale antikörper gegen den tgf-beta ii rezeptor und dessen medizinische verwendung | |
| EP0815125A4 (de) | gC1q-REZEPTOR, DARAN BINDENDE HIV-1 gp120-REGION, VERWANDTE PEPTIDE UND ANTIKÖRPER | |
| ATE194291T1 (de) | Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus | |
| NO975546D0 (no) | Antigene gruppe B-streptokokk-type II- og type III-polysakkaridfragmenter med en 2,5-anhydro-D-mannose-terminal struktur samt en konjugatvaksine derav | |
| BR9809656A (pt) | Composição imunopotencializante | |
| BR9912176A (pt) | Epìtopos de célula auxiliar t artificial como estimuladores imunes para imunógenos de peptìdeo sintéticos incluindo peptìdeos de lhrh imunogênicos | |
| EE200100549A (et) | Meetod fibroosi ravimiseks integriini alfa-4 subühiku antagonistide abil | |
| HUP9701586A2 (hu) | Javított inaktivált vakcinák | |
| TR200102034T2 (tr) | Anti kanser aşılaması için antikorların kullanılması | |
| JP2002534481A5 (de) | ||
| ATE248601T1 (de) | Impfstoff gegen rotavirus infektionen enthaltend peptide des viralenterotoxines nsp4 | |
| ES2143996T3 (es) | Antigenos peptidicos del hcv y procedimiento para la determinacion del hcv. | |
| DE60313437D1 (de) | Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4 | |
| RU98112608A (ru) | Иммуногенная композиция [на основе] tlp | |
| WO1999025375A3 (en) | DIRECT CYTOTOXIC ACTIVITY BY ANTI-hCG MONOCLONAL ANTIBODIES | |
| WO2002000250A3 (en) | Hiv-1 vaccines and screening methods therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |